Apixaban Price In Korea

• Korea: 43,000 USD/Ton

The price of apixaban in the Korea for Q1 2024 reached 43,000 USD/Ton in March.

The latest report by IMARC Group, titled "Apixaban Pricing Report 2024: Price Trend, Chart, Market Analysis, News, Demand, Historical and Forecast Data," provides a thorough examination of the Apixaban Prices. This report delves into the price of Apixaban globally, presenting a detailed analysis, along with informative Price Chart. Through comprehensive Price analysis, the report sheds light on the key factors influencing these trend. Additionally, it includes historical data to offer context and depth to the current pricing landscape. The report also explores the Demand, analyzing how it impacts market dynamics. To aid in strategic planning, the price forecast section provides insights into price forecast, making this report an invaluable resource for industry stakeholders.

Report Offering:

• Monthly Updates: Annual Subscription
• Quarterly Updates: Annual Subscription
• Biannually Updates: Annual Subscription

The study delves into the factors affecting Apixaban price variations, including alterations in the cost of raw materials, the balance of supply and demand, geopolitical influences, and sector-specific developments.

The report also incorporates the most recent updates from the market, equipping stakeholders with the latest information on market fluctuations, regulatory modifications, and technological progress. It serves as an exhaustive resource for stakeholders, enhancing strategic planning and forecast capabilities.

Request For a Sample Copy of the Report: https://www.imarcgroup.com/apixaban-pricing-report/requestsample 

Apixaban Price Trend Last Quarter

Apixaban is an oral anticoagulant medication that belongs to the class of direct oral anticoagulants (DOACs) and works by inhibiting Factor Xa, a key enzyme in the blood coagulation process. By blocking Factor Xa, Apixaban helps prevent the formation of blood clots, making it an essential medication for patients at risk of venous thromboembolism (VTE), atrial fibrillation (AF), and other conditions associated with an increased risk of blood clots.

Approved by various regulatory authorities, including the FDA and the European Medicines Agency (EMA), Apixaban is widely prescribed for preventing stroke and systemic embolism in patients with non-valvular AF, as well as for treating deep vein thrombosis (DVT) and pulmonary embolism (PE).

One of the key benefits of Apixaban is its predictable pharmacokinetics and pharmacodynamics, which allows for fixed dosing without the need for routine coagulation monitoring, unlike traditional anticoagulants such as warfarin. Its oral administration and lower risk of major bleeding events also make it a preferred choice for many healthcare providers. The convenience, efficacy, and safety profile of Apixaban have made it a cornerstone in the management of thromboembolic disorders, with increasing demand across various healthcare sectors.

Apixaban Industry Analysis

 The global apixaban market is primarily driven by the increasing prevalence of cardiovascular diseases, particularly atrial fibrillation, which poses a high risk of stroke, and fuels the demand for anticoagulant medications such as apixaban. As the aging population grows and lifestyles become more sedentary, there has been a rise in the incidence of atrial fibrillation, thereby propelling the market growth.

Additionally, the superior safety and efficacy profile of apixaban compared to traditional anticoagulants such as warfarin have accelerated the product adoption rate. Unlike warfarin, Apixaban does not require frequent monitoring of blood levels and has a lower risk of major bleeding, making it more convenient and safer for patients.

 Apart from this, the expanding awareness among healthcare professionals about the benefits of direct oral anticoagulants (DOACs) such as apixaban, coupled with favorable reimbursement policies in many regions, further drive market growth. Moreover, ongoing research and development (R&D) activities focused on expanding the indications for Apixaban, such as its potential use in preventing recurrent venous thromboembolism and reducing the risk of cardiovascular events in patients with recent acute coronary syndrome, are expected to fuel market expansion in the coming years.

Regional Price Analysis:

• Asia Pacific: China, India, Indonesia, Pakistan, Bangladesh, Japan, Philippines, Vietnam, Thailand, South Korea, Malaysia, Nepal, Taiwan, Sri Lanka, Hongkong, Singapore, Australia, and New Zealand.
• Europe: Germany, France, United Kingdom, Italy, Spain, Russia, Turkey, Netherlands, Poland, Sweden, Belgium, Austria, Ireland, Switzerland, Norway, Denmark, Romania, Finland, Czech Republic, Portugal and Greece.
• North America: United States and Canada.
• Latin America: Brazil, Mexico, Argentina, Columbia, Chile, Ecuador, and Peru
• Middle East & Africa: Saudi Arabia, UAE, Israel, Iran, South Africa, Nigeria, Oman, Kuwait, Qatar, Iraq, Egypt, Algeria, and Morocco.

Note: The current country list is selective, detailed insights into additional countries can be obtained for clients upon request.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145